Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review

Omar Azuara Antonio; Erika Rubí De La Cruz-Elizaldeb; José Eduardo Carmona-Rodriguez; Lesly Idaliht Hernandez-Martinez

doi:10.29057/mjmr.v14i28.16493

Authors

Omar Azuara Antonio Hospital General de Pachuca IMSS Bienestar https://orcid.org/0000-0002-8648-4573
Erika Rubí De La Cruz-Elizaldeb Instituto de Ciencias y Estudios Superiores de Tamaulipas
José Eduardo Carmona-Rodriguez Universidad Autónoma del Estado de Hidalgo https://orcid.org/0009-0002-9952-3356
Lesly Idaliht Hernandez-Martinez Universidad Autónoma del Estado de Hidalgo https://orcid.org/0009-0002-2027-9574

DOI:

https://doi.org/10.29057/mjmr.v14i28.16493

Keywords:

Psilocybe, mushrooms, poisoning, pathophysiology, treatment

Abstract

The Psilocybe cubensis mushroom is recognized as the primary source of psilocybin in the Americas, occurring naturally across various regions. This fungus has a long history of use in Mesoamerican rituals due to its capacity to induce altered states of consciousness. The defining characteristic of Psilocybe mushrooms is their psilocybin content. Following ingestion, psilocybin is metabolized into psilocin, which acts as a potent serotonergic agonist by interacting with serotonin receptors. The resulting physiological and psychoactive effects are linked to the activity at 5-HT receptors within the central nervous system, along with the release of glutamate. Throughout history, diverse Mesoamerican cultures incorporated hallucinogenic mushroom consumption into their ritual ceremonies. The Aztecs, for example, revered them as Teonanácatl, or " flesh of the gods," valuing their ability to shift the perception of reality. Interest in psilocybin has seen a resurgence in the scientific community, spanning from the ethnobotanical studies of R. Gordon Wasson in the 1950s to contemporary research into its therapeutic applications for depression. Studies have indicated that psilocybin can sustainably alleviate depressive symptoms, often with fewer side effects compared to conventional pharmacological treatments. The combination of the ancient ceremonial and religious use of Psilocybe mushrooms with their demonstrable therapeutic potential is prompting a reevaluation of their legal status as a Schedule I drug. Ongoing research is actively exploring the impact of psilocybin on various psychiatric disorders, yielding promising results, particularly in the treatment of major depressive disorder. As the evidence supporting its therapeutic benefits continues to accumulate, it suggests a future where these psychedelic compounds could play a vital role in global mental health.

Downloads

Download data is not yet available.

References

[1] Stebelska K. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Ther. Drug Monit. 2013; 35(4): 420-42.

[2] Patocka J, Wu R, Nepovimova E, Valis M, Wu W, Kuca K. Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms. Int. J. Mol. Sci. 2021; 22(4): 2218.

[3] Kosentka P, Sprague SL, Ryberg M, Gartz J, May AL, Campagna SR, et al. Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi. PLoS One. 2013; 8(5): e64646.

[4] Carod-Artal FJ. Neurological syndromes associated with the ingestion of plants and fungi with a toxic component (II). Hallucinogenic fungi and plants, mycotoxins and medicinal herbs. Rev. Neurol. 2003; 36(10): 951–60.

[5] Manzanilla, L. & Lujan. L. L. Historia antigua de México: Aspectos fundamentales de la tradición cultural mesoamericana. 1a ed México: UNAM; 2000

[6] Carod-Artal FJ, Vázquez-Cabrera CB. An anthropological study about epilepsy in native tribes from Central and South America. Epilepsia. 2007; 48(5): 886-93.

[7] Schultes, R. E. Who uses hallucinogenic plants?; Plants of the Gods: their sacred, healing, and hallucinogenic powers. E.U: CreateSpace; 2001: 62-65.

[8] Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2015; 30(1): 42-9.

[9] Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci. 2010; 11(9): 642-51.

[10] Duchi Ñauta P. La psilocibina, sustancia psicodélica del hongo orientada a ser el nuevo enfoque de la medicina.” Rev. Juv. Cie. Sol. 2022; 12: 57-9.

[11] Yilmaz I, Kaya E, Sinirlioglu ZA, Bayram R, Surmen MG, Colakoglu S. Clinical importance of toxin concentration in Amanita verna mushroom. Toxicon. 2014; 87: 68-75.

[12] Mckenna, terence k. Food of the gods. Bantam, 1992.

[13] Rodríguez Arce JM, Winkelman MJ. Psychedelics, Sociality, and Human Evolution. Front. Psychol. 2021; 12: 729425.

[14] Nichols DE. Psilocybin: from ancient magic to modern medicine. J. Antibiot (Tokyo). 2020; 73(10): 679-86.

[15] R. Gordon Wasson. A velada in Huautla. The Wondrous Mushroom. Mycolatry in Mesoamerica. United States of America: Sungazer Press 2021. Pág 3-31

[16] Hofmann A, Heim R, Brack A, Kobel H, Frey A, Ott H. Psilocybin und psilocin, zwei psychotrope wirkstoffe aus mexikanischen rauschpilzen. Helvetica Chimica Acta. 1959; 42(5): 1557-72.

[17] Zeiss R, Gahr M, Graf H. Rediscovering Psilocybin as an Antidepressive Treatment Strategy. Pharmaceuticals (Basel). 2021; 14(10): 985.

[18] Lieberman JA, Shalev D. Back to the future: Research renewed on the clinical utility of psychedelic drugs. J. Psychopharmacol. 2016; 30(12): 1198-1200.

[19] Marks M, Cohen IG. Psychedelic therapy: a roadmap for wider acceptance and utilization. Nat. Med. 2021; 27(10): 1669-1671.

[20] Mithoefer MC, Grob CS, Brewerton TD. Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry. 2016; 3(5): 481-8.

[21] World Health Organization. Depression [Internet]. World health organization, world health organization, 2019 [cited 2025 January

25]. Available from: https://www.who.int/health-topics/depression#tab=tab_1

[22] Bogenschutz MP, Ross S. Therapeutic Applications of Classic Hallucinogens. Curr. Top. Behav. Neurosci. 2018; 36: 361-91.

[23] Johnson MW, Griffiths RR. Potential Therapeutic Effects of Psilocybin. Neurotherapeutics. 2017; 14(3): 734-740.

[24] Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and Other Psychoplastogens for Treating Mental Illness. Front. Psychiatry. 2021; 12: 727117.

[25] Schmutz M, Carron PN, Yersin B, Trueb L. Mushroom poisoning: a retrospective study concerning 11-years of admissions in a swiss emergency department. Int. Emerg. Med. 2016; 13(1): 59–67.

[26] Moreno G, Manjón JLG. Guía de hongos de la Península Ibérica: con la descripción de 584 especies más de 1000 fotografiás en color y numerosos dibujos. Turín, Italia: Omega; 2010.

[27] Bonnet MS, Basson PW. The toxicology of Amanita phalloides. Homeopathy. 2002; 91(4): 249-54.

[28] Palmier Peláez, Esmeralda. Estudio epidemiológico de la intoxicación aguda por setas [Trabajo de grado]. Valladolid, España: Universidad de Valladolid. Facultad de Medicina; 2016”

[29] Erden A, Esmeray K, Karagöz H, Karahan S, Gümüşçü HH, Başak M. Acute liver failure caused by mushroom poisoning: a case report and review of the literature. Int. Med. Case Rep. J. 2013; 6: 85-90.

[30] Diaz JH. Amatoxin-Containing Mushroom Poisonings: Species, Toxidromes, Treatments, and Outcomes. Wilderness Environ Med. 2018; 29(1): 111-8.

[31] Alvarado P, Gasch-Illescas A, Morel S, Dagher-Kharrat MB, Moreno G, Manjón JL, et al. Amanita Section Phalloideae Species in the Mediterranean Basin: Destroying Angels Reviewed. Biology (Basel). 2022; 11(5): 770.

[32] Keller SA, Klukowska-Rötzler J, Schenk-Jaeger KM, Kupferschmidt H, Exadaktylos AK, Lehmann B, et al. Mushroom Poisoning-A 17 Year Retrospective Study at a Level I University Emergency Department in Switzerland. Int. J. Environ. Res. Public Health. 2018; 15(12): 2855.

[33] Colak S, Kandis H, Afacan MA, Erdogan MO, Gunes H, Kaya E, et al. Assessment of patients who presented to the emergency department with mushroom poisoning. Hum. Exp. Toxicol. 2015; 34(7): 725-31.

[34] Ahishali E, Boynuegri B, Ozpolat E, Surmeli H, Dolapcioglu C, Dabak R, et al. Approach to mushroom intoxication and treatment: can we decrease mortality? Clin. Res. Hepatol. Gastroenterol. 2012; 36(2): 139-45.

[35] Grabhorn E, Nielsen D, Hillebrand G, Brinkert F, Herden U, Fischer L, et al. Successful outcome of severe Amanita phalloides poisoning in children. Pediatr. Transplant. 2013; 17(6): 550-5.

[36] Ramírez-Terrazo A, Garibay-Orijel R, Reyes-Chilpa R, Casas A, Méndez-Espinoza C. Alternativas para la atención oportuna de las intoxicaciones por consumo de hongos en México y Centroamérica. Gac Med Mex [Internet]. 2023;159(4). Disponible en: http://dx.doi.org/10.24875/gmm.23000101

[37] Garcia J, Costa VM, Carvalho A, Baptista P, de Pinho PG, de Lourdes Bastos M, et al. Amanita phalloides poisoning: Mechanisms of toxicity and treatment. Food Chem. Toxicol. 2015; 86: 41-55.

[38] Sun J, Niu YM, Zhang YT, Li HJ, Yin Y, Zhang YZ, et al. Toxicity and toxicokinetics of Amanita exitialis in beagle dogs. Toxicon. 2018; 143: 59-67.

[39] Piqueras J. Hepatotoxic mushroom poisoning: diagnosis and management. Mycopathologia. 1989; 105(2): 99-110.

[40] Jaeger A, Jehl F, Flesch F, Sauder P, Kopferschmitt J. Kinetics of amatoxins in human poisoning: therapeutic implications. J. Toxicol. Clin. Toxicol. 1993; 31(1): 63-80.

[41] Bever CS, Swanson KD, Hamelin EI, Filigenzi M, Poppenga RH, Kaae J, et al. Rapid, Sensitive, and Accurate Point-of-Care Detection of Lethal Amatoxins in Urine. Toxins (Basel). 2020; 12(2): 123.

[42] Toxicidad neurológica, Efectos tóxicos. Josep Piqueras [Internet]. Fungimag.com. [citado el 31 de octubre de 2025]. Disponible en: https://www.fungimag.com/spring-2021-articles/Morel%20Toxicity%20Update.pdf

[43] Najar D, Haraldsson B, Thorsell A, Sihlbom C, Nyström J, Ebefors K. Pharmacokinetic Properties of the Nephrotoxin Orellanine in Rats. Toxins (Basel). 2018; 10(8): 333.

[44] Dinis-Oliveira RJ, Soares M, Rocha-Pereira C, Carvalho F. Human and experimental toxicology of orellanine. Hum. Exp. Toxicol. 2016; 35(9): 1016-29.

[45] White J, Weinstein SA, De Haro L, Bédry R, Schaper A, Rumack BH, et al. Mushroom poisoning: A proposed new clinical classification. Toxicon. 2019; 157: 53-65.

[46] Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. Eur J Emerg Med. 2005; 12(2): 78-85.

[47] Graeme KA. Mycetism: a review of the recent literature. J. Med. Toxicol. 2014; 10(2): 173-89.

[48] Nef HM, Möllmann H, Hilpert P, Krause N, Troidl C, Weber M, et al. Apical regional wall motion abnormalities reminiscent to Tako-Tsubo cardiomyopathy following consumption of psychoactive fungi. Int. J. Cardiol. 2009; 134(1): e39-41.

[49] Wennig R, Eyer F, Schaper A, Zilker T, Andresen-Streichert H. Mushroom Poisoning. Dtsch .Arztebl. Int. 2020; 117(42): 701-8.

[50] Pauli JL, Foot CL. Fatal muscarinic syndrome after eating wild mushrooms. Med J Aust. 2005; 182(6): 294-5.

[51] Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit. Care Med. 2005; 33(2): 419-26.

[52] Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med. 2005; 33(2): 427-36.

[53] Nogué S, Simón J, Blanché C, Piqueras J, Menarini L. Intoxicaciones por plantas y setas [Internet]. Wordpress.com. [citado el 31 de octubre de 2025]. Disponible en: https://joseppiqueras.wordpress.com/wp-content/uploads/2016/06/2009-menarini.pdf

[54] Stebelska K. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Ther. Drug Monit. 2013; 35(4): 420-42.

[55] Flammer R, Schenk-Jäger KM. Pilzvergiftungen--die Schattenseiten des Myzetismus [Mushroom poisoning--the dark side of mycetism]. Ther Umsch. 2009; 66(5): 357-64.

[56] Lima ADL, Costa Fortes R, Garbi Novaes MRC, Percário S.. Poisonous mushrooms; a review of the most common intoxications. Nutr. Hosp. 2012; 27(2): 402-8.

[57] Piqueras-Carrasco J. Intoxicaciones por setas, una actualización. Rev. Esp. Med. Legal. 2014; 40(1): 19–29.

[58] Lagrange E, Vernoux JP, Reis J, Palmer V, Camu W, Spencer PS. An amyotrophic lateral sclerosis hot spot in the French Alps associated with genotoxic fungi. J. Neurol. Sci. 2021; 427: 117558.

[59] Mayer JH, Herlocher JE, Parisian J. Esophageal rupture after mushroom-alcohol ingestion. 1971; 285(23): 1323

[60] Kretz O, Creppy EE, Dirheimer G. Characterization of bolesatine, a toxic protein from the mushroom Boletus satanas Lenz and it's effects on kidney cells. Toxicology. 1991; 66(2): 213-24.

[61] Keller SA, Klukowska-Rötzler J, Schenk-Jaeger KM, Kupferschmidt H, Exadaktylos AK, Lehmann B, et al. Mushroom Poisoning-A 17 Year Retrospective Study at a Level I University Emergency Department in Switzerland. Int. J. Environ. Res. Public Health. 2018; 15(12): 2855.

[62] Gachet C, Ennamany R, Kretz O, Ohlmann P, Krause C, Creppy EE, et al. Bolesatine induces agglutination of rat platelets and human erythrocytes and platelets in vitro. Hum. Exp. Toxicol. 1996; 15(1): 26-9.

[63] Schenk-Jaeger KM, Rauber-Lüthy C, Bodmer M, Kupferschmidt H, Kullak-Ublick GA, Ceschi A. Mushroom poisoning: a study on circumstances of exposure and patterns of toxicity. Eur. J. Intern. Med. 2012; 23(4): e85-91.

[64] Bernardino Sahagun RP. Historia general de las cosas de nueva España: Tomo 1. Outlook Verlag; 2022.